QSIAW — Quantum-Si incorporated

Summary of Quantum-Si Incorporated Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: $258,000, primarily from Platinum instruments and consumables.
• Gross Profit: $74,000, with a gross margin of 29%, influenced by a higher proportion of consumables sold.
• Operating Expenses: GAAP operating expenses were $24.1 million, down from $25.6 million in Q1 2025. Adjusted operating expenses were $21.4 million, compared to $22.9 million in the prior year.
• Cash Position: As of March 31, 2026, the company had $190.4 million in cash, cash equivalents, and marketable securities.
• Outlook: Expected total revenue for 2026 is approximately $1 million, with adjusted operating expenses capped at $98 million.

2. Strategic Updates and Business Highlights:

• Proteus Development: Significant progress made, including successful sequencing on integrated Proteus instruments. The platform is expected to outperform the existing Platinum technology in terms of automation, throughput, and proteome coverage.
• Market Preparation: Initiatives include a roadshow series to educate potential customers about Proteus and its capabilities. Early interest has been strong, particularly regarding applications in post-translational modifications (PTMs).
• Customer Engagement: Positive feedback from early access customers using the Proteus prototype, indicating improvements in amino acid detection and read lengths compared to Platinum.

3. Forward Guidance and Outlook:

• 2026 Focus: The year is viewed as a transition period, with expectations of modest revenue growth as customers await the Proteus launch.
• Long-term Goals: Management believes Proteus will drive future revenue growth and profitability, with plans to maintain fiscal discipline while funding strategic initiatives.
• Cash Runway: The current cash position is projected to support operations into 2028, allowing for flexibility in managing expenses post-Proteus launch.

4. Bad News, Challenges, or Points of Concern:

• Revenue Generation: Current revenue is low, reflecting a transition phase as customers delay purchases until the Proteus launch.
• Operating Expense Management: While expenses have decreased, the company is still investing heavily in R&D, which could strain resources if revenue does not increase as anticipated.
• Market Risks: The reliance on external partners for manufacturing and development could pose risks if there are delays or issues in scaling production.

5. Notable Q&A Insights:

• Customer Experience with Proteus: Enhanced capabilities in amino acid detection and longer read lengths are expected to improve customer applications significantly, particularly in complex protein mixtures and PTMs.
• Volume Expectations: While it is difficult to predict exact volume increases when switching from Platinum to Proteus, management anticipates that Proteus will open up new applications and customer segments, potentially increasing utilization.
• Early Access Program: The selection process for early access sites will focus on a mix of academic and commercial environments to gather diverse data and experiences.
• Roadshow Feedback: Customers are excited about the potential of Proteus, especially for PTM analysis, and initial pricing feedback has been positive, with no significant pushback noted.

Overall, Quantum-Si is in a critical transition phase as it prepares for the launch of its Proteus platform, with a focus on maintaining financial strength while driving customer engagement and market education.